Liberum Capital restated their buy rating on shares of Udg Healthcare (LON:UDG) in a report issued on Tuesday morning, ThisIsMoney.Co.Uk reports.
Several other analysts have also issued reports on UDG. Jefferies Financial Group boosted their target price on Udg Healthcare from GBX 620 ($8.16) to GBX 735 ($9.67) and gave the company a hold rating in a research note on Tuesday, January 21st. Peel Hunt reissued a buy rating on shares of Udg Healthcare in a report on Friday, May 8th. Royal Bank of Canada raised shares of Udg Healthcare to an outperform rating and dropped their price objective for the company from GBX 800 ($10.52) to GBX 730 ($9.60) in a report on Friday, March 20th. Barclays lifted their target price on shares of Udg Healthcare from GBX 830 ($10.92) to GBX 910 ($11.97) and gave the stock an overweight rating in a research note on Tuesday, January 21st. Finally, Berenberg Bank dropped their price target on shares of Udg Healthcare from GBX 920 ($12.10) to GBX 750 ($9.87) and set a buy rating on the stock in a research note on Wednesday, March 25th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Udg Healthcare presently has a consensus rating of Buy and a consensus price target of GBX 886.67 ($11.66).
Shares of UDG stock opened at GBX 700 ($9.21) on Tuesday. Udg Healthcare has a 52-week low of GBX 423.40 ($5.57) and a 52-week high of GBX 846 ($11.13). The company has a debt-to-equity ratio of 26.65, a quick ratio of 1.43 and a current ratio of 1.59. The firm has a fifty day moving average of GBX 615.80 and a 200-day moving average of GBX 719.35. The stock has a market cap of $1.76 billion and a price-to-earnings ratio of 30.57.
Udg Healthcare Company Profile
UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services in the Republic of Ireland, the United Kingdom, North America, and internationally. The company operates in two segments, Ashfield and Sharp. The Ashfield segment offers commercialization services for the pharmaceutical and healthcare industry in the areas of advisory, communications, and commercial and clinical services.
Recommended Story: How to interpret Moving Average Convergence Divergence (MACD)
Receive News & Ratings for Udg Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Udg Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.